8 May 2026 - Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following the successful negotiation of a commercial deal to make the medicine available on the NHS.

Today’s final draft guidance says givinostat (Duvyzat, ITF Pharma) can be used to treat Duchenne muscular dystrophy in people aged 6 and over who are able to walk or stand, with or without support, at the start of treatment. This is in line with the populations studied in clinical trials rather than the full licensed population.

Givinostat has been available since November 2024 under an early access programme.

Read NICE press release